(0)
TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile
Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current thrombolytics are limited in use due in part to increased risks of bleeding
Phase 2a study demonstrated positive impacts on blood vessel reopening and patient functional recovery with no incidence of symptomatic intracranial hemorrhage
Biogen to make a one-time payment of $18 million and may pay potential milestone payments and royalties to TMS Co., Ltd.
CAMBRIDGE, Mass. and FUCHU-SHI, Tokyo, May 12, 2021Inc (Nasdaq: BIIB) and TMS Co., Ltd. announced today that Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen s decision to acquire TMS-007 was based on positive data from a Phase 2a study. The study met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH) and demonstrated positive imp
Brinton Pharma triples up production of COVID-19 drug Favipiravir
Brinton Pharma triples up production of COVID-19 drug Favipiravir
12 May 2021 | News Also increased the production of additional drugs Scabover & Iverbond (Ivermectin 12 mg ) Tablet and Doxybond LB & Briodox (Doxycycline) Tablet
Image credit- shutterstock.com
Pune based Brinton Pharmaceuticals has more than triple up the production of Faviton (Favipiravir 400) tablet, the Covid-19 drug. Favipiravir is used as an oral antiviral therapy for mild to moderate cases of Covid-19.
It has also increased the production of additional drugs Scabover & Iverbond (Ivermectin 12 mg ) Tablet and Doxybond LB & Briodox (Doxycycline) Tablet which are also used towards the treatment of covid-19.
Several people were arrested over a weekend drug investigation during which police reported finding large amounts of drugs, firearms and cash in both Floyd County and Pikeville.